Sorry, you need to enable JavaScript to visit this website.

Pfizer Statement on Conducting Clinical Trials in Response to the FDA Letter Dated April 9, 2010

Patient safety is a top priority for Pfizer. Pfizer conducts clinical trials globally according to the highest ethical and scientific standards. To ensure compliance with good clinical practice and regulatory agencies globally, Pfizer continually enhances our systems for managing clinical trials.

Pfizer recognizes the seriousness of the issues cited by the FDA and is committed to fully addressing FDA's concerns. Many of the items cited by the FDA were first uncovered and reported to the FDA by Pfizer as far back as four years ago as part of our ongoing clinical trial monitoring and quality assurance processes. Since that time, Pfizer has instituted several new measures designed to improve monitoring and execution of clinical trials, including our oversight of clinical investigators.

Pfizer has communicated with the FDA about our conduct of clinical trials and, over the next two weeks, will provide an outline of new and existing processes for preventing similar issues with Pfizer clinical trials in the future.